Enanta Pharma (ENTA) Tops Q3 EPS by 39c, beats revenue

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.86), $0.39 better than the analyst estimate of ($2.25). Revenue for the quarter came in at $18.89 million versus the consensus estimate of $18.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue